Abstract 3743
Background
The identification of HER2 overexpression in a subset of gastric cancer (GC) patients represents a significant step forward in unveiling the molecular complexity of this disease. The predictive and prognostic value of HER2 amplification in advanced HER2 inhibitor-treated GC patients has been investigated. However, its predictive value in early stage resectable patients remains unclear. In this study we interrogated the correlation between HER2 copy number (CN) and disease-free survival (DFS).
Methods
We enrolled 98 treatment-naïve resectable (stage I-III) Chinese GC patients with HER2 overexpression assessed using IHC. Capture-based targeted sequencing using a panel consisting of 41 gastrointestinal cancer -related genes was performed on FFPE samples. Furthermore, we also investigated the correlation between HER2 CN and DFS. This cohort had 81 males and 17 females, with a median age of 64. 12, 62 and 24 patients had diffuse, intestinal and mixed GC respectively.
Results
Of the 98 HER2-overexpressed patients assessed using IHC, 91 had HER2 CN amplification assessed using next-generation sequencing, achieving 93% concordance. In addition, 10 had concurrent HER2 missense mutations, including 4 with S310X. All patients except for two had at least one concurrent mutation. The most commonly seen concurrent mutations were TP53, EGFR and PIK3CA, occurring in 85%, 13% and 12% patients, respectively. Furthermore, 23 patients had mutations in EGFR, MET, PDGFRA or KIT, which may participate in the activation of bypass pathways. We also revealed that patients with concurrent TP53 (p = 0.05) or PI3KCA (p = 0.02) mutations were significantly older than patients without. Next, dichotomous analysis was performed to investigate the association between HER2 CN and DFS. Stage I patients did not undergo adjuvant chemotherapy and all stage II-III patients underwent adjuvant chemotherapy. Our study revealed that patients with high HER2 CN had a significantly shorter DFS than patients with low HER2 CN (p = 0.002).
Conclusions
We elucidated the mutation spectrum of HER2-amplified resectable Chinese GC patients and the association between HER2 CN and DFS. Our study revealed the predictive value of HER2 CN and allowed us to further stratify HER2-positive patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract